SCHEMBL17377185

SCHEMBL17377185

Cn1ncc2c1CN(CC(O)CNC(=O)O)CC2

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 20/20 0.52
▸ WDR77 Q9BQA1 18/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17383257 0.85 PRMT5 (0.51) PRMT5WDR77
SCHEMBL19164213 0.81 PRMT5 (0.51) PRMT5WDR77
SCHEMBL17377104 0.80 PRMT5 (0.53) PRMT5WDR77
SCHEMBL17377026 0.80 PRMT5 (0.53) PRMT5WDR77
SCHEMBL15825326 0.75 PRMT5 (0.79) PRMT5WDR77
SCHEMBL19170595 0.75 PRMT5 (0.73) PRMT5WDR77
SCHEMBL19171127 0.74 PRMT5 (0.76) PRMT5WDR77
SCHEMBL19171121 0.74 PRMT5 (0.72) PRMT5WDR77
SCHEMBL17377142 0.73 PRMT5 (0.64) PRMT5WDR77
SCHEMBL17377139 0.73 PRMT5 (0.64) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 — — US disclosed
EP-3160466-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-05-03 — — EP disclosed
WO-2015200677-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885WDR77 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback